Home › Biopharmaceuticals
Biopharmaceuticals Market Research Reports & Consulting
Market Reports
| Title | Published | Price | TOC Available |
|---|---|---|---|
Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024The regenerative medicine market is projected to reach USD 38.7 billion by 2024 from USD 13.3 billion in 2019, at a CAGR of 23.8%. Market growth is largely driven by the rising prevalence of chronic diseases and genetic disorders, growing government investments in regenerative medicine research, and the increasing number of regenerative medicine companies globally.Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US). |
October 2019 | $ 5650 |
|
Metagenomic Sequencing Market by Workflow (Sample Preparation, Data Analysis), Product & Services (Reagents, Consumables, Instruments), Technology (Shotgun, 16s Rrna, Whole-Genome), Application (Diagnostic, Soil Microbiome) - Global Forecast to 2024The metagenomic sequencing market is expected to grow from USD 1.0 billion in 2019 to USD 2.3 billion by 2024, at a compound annual growth rate (CAGR) of 17.0% during the forecast period.The major players operating in the global metagenomic sequencing market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc (US), QIAGEN N.V. (Netherlands), PerkinElmer (US), Oxford Nanopore Technologies Ltd (UK), BGI Group (China), Macrogen Inc. (South Korea), GENEWIZ (US), Eurofins Scientific (Luxembourg), Novogene Corporation (China), Zymo Research Corporation (US), NuGEN Technologies, Inc (US), IntegraGen SA (France), Microsynth AG (Switzerland), and DNAStar, Inc (US). |
September 2019 | $ 5650 |
|
Biosimilars Market by Disease (Oncology, Autoimmune), Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract) - Global Forecast to 2023The overall biosimilars market is expected to reach $23.63 Billion by 2023 from $5.95 Billion in 2018, at a CAGR of 31.7%. Market growth is primarily driven by the increasing demand for biosimilar drugs due to their cost-effectiveness, increasing incidences of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities. Key players in the biosimilars market include Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), and Samsung Biologics (South Korea). |
April 2018 | $ 5650 |
|
Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.
Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement
Connect With Us
Live Chat Support
Search reports
'Connect With Us
